Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) following autologous marrow transplantation in man.
The use of rhGM-CSF following autologous marrow transplantation for lymphoid malignancies was explored in a Phase I-II dose escalation study. rhGM-CSF given as a 2 hour infusion for 14 days was well tolerated at doses up to 240 micrograms/m2/day. At doses of 60 micrograms/m2/day or more, rhGM-CSF appeared to have biologic activity accelerating both neutrophil and platelet recovery.
Appelbaum
F R
FR
Fred Hutchinson Cancer Research Center, Seattle, Washington.
Nemunaitis
J
J
D000328:Adult; D016026:Bone Marrow Transplantation; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007958:Leukocyte Count; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D010976:Platelet Count; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000601:surgery; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014182:Transplantation, Autologous
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor